Pharmacological Management of Diabetes

Correct Answer

C — Liraglutide

Rationale

Liraglutide is a glucagon-like peptide-1 receptor agonist, along with semaglutide, dulaglutide, exenatide, and lixisenatide. Sitagliptin is a dipeptidyl peptidase-4 inhibitor. Pioglitazone is a thiazolidinedione. Metformin is a biguanide.

Correct Answer

A — Exenatide

Rationale

Exenatide is an exendin-4-based glucagon-like peptide-1 receptor agonist, sharing approximately 53 percent homology with human glucagon-like peptide-1 and derived from a peptide found in the saliva of the Gila monster lizard. Lixisenatide is the other exendin-4-based agent. Liraglutide, semaglutide, and dulaglutide are classified as human glucagon-like peptide-1 analogs engineered from the native human sequence.

Correct Answer

D — Glucagon-like peptide-1 receptor agonist

Rationale

Dulaglutide is classified as a glucagon-like peptide-1 receptor agonist, along with liraglutide, semaglutide, exenatide, and lixisenatide. Dipeptidyl peptidase-4 inhibitors include sitagliptin, saxagliptin, linagliptin, and alogliptin. Sulfonylureas include glipizide, glyburide, and glimepiride. Thiazolidinediones include pioglitazone and rosiglitazone.

Correct Answer

B — Glucagon-like peptide-1 receptor agonist

Rationale

Semaglutide is classified as a glucagon-like peptide-1 receptor agonist, specifically a human glucagon-like peptide-1 analog. Alpha-glucosidase inhibitors include acarbose and miglitol. Meglitinides include repaglinide and nateglinide. Metformin is the only biguanide in current clinical use.

Correct Answer

A — Liraglutide

Rationale

Liraglutide is classified as a human glucagon-like peptide-1 analog, engineered from the native human glucagon-like peptide-1 sequence with modifications — including a fatty acid chain — that extend its half-life. Semaglutide, dulaglutide, and albiglutide are also human glucagon-like peptide-1 analogs. Exenatide and lixisenatide are classified as exendin-4-based agents, derived from the Gila monster peptide with approximately 53 percent homology to human glucagon-like peptide-1. The human analog versus exendin-4-based distinction is pharmacologically relevant because cardiovascular outcome trial benefit has emerged primarily with the human analog subclass.

Correct Answer

C — Semaglutide

Rationale

Semaglutide is the only glucagon-like peptide-1 receptor agonist available as an oral tablet formulation, in addition to a once-weekly subcutaneous injection. The oral formulation uses an absorption enhancer to facilitate peptide absorption across the gastric mucosa and must be taken fasting. Exenatide, liraglutide, and dulaglutide are available only as subcutaneous injections.

Correct Answer

B — Glucagon-like peptide-1 receptor agonists amplify insulin secretion only when blood glucose is elevated; the receptor signaling pathway is inactive when glucose is at fasting levels, preventing insulin-driven hypoglycemia

Rationale

Glucagon-like peptide-1 receptor agonists signal through Gs protein coupling to activate adenylyl cyclase, raise intracellular cyclic adenosine monophosphate, and activate protein kinase A in pancreatic beta cells. This pathway amplifies glucose-stimulated insulin secretion — it augments the beta cell response to glucose, but only when glucose is present and elevated. When blood glucose is at fasting or normal levels, the insulinotropic signal from glucagon-like peptide-1 receptor activation is minimal. Sulfonylureas close adenosine triphosphate-sensitive potassium channels independent of blood glucose, driving insulin secretion even when glucose is already normal or low. Glucagon-like peptide-1 receptor agonists do not completely suppress glucagon under all conditions — glucagon suppression is also glucose-dependent — and they do not stimulate glucagon secretion. The distinction with sulfonylureas is qualitative, not quantitative.

Correct Answer

D — Glucagon-like peptide-1 receptors in the hypothalamus and brainstem reduce appetite and increase satiety when activated, leading to reduced food intake and weight loss

Rationale

Glucagon-like peptide-1 receptors are expressed in appetite-regulating circuits in the hypothalamus and brainstem, including areas involved in satiety signaling such as the nucleus tractus solitarius and area postrema. Activation of these central receptors reduces appetite and promotes satiety, leading to decreased food intake and sustained weight loss. These central nervous system effects are mediated primarily through vagal afferents and circumventricular organs that lack the blood-brain barrier, rather than by the drug crossing the blood-brain barrier directly. Glucagon-like peptide-1 receptor agonists do not cause malabsorptive weight loss, do not activate lipolysis in adipocytes through direct receptor stimulation, and do not raise resting metabolic rate through skeletal muscle activation.

Correct Answer

A — Glucagon-like peptide-1 receptor activation slows gastric emptying, delaying the movement of food from the stomach into the small intestine and producing nausea, early satiety, and vomiting

Rationale

Glucagon-like peptide-1 receptors are expressed in the gastrointestinal tract and their activation slows gastric emptying as part of the normal incretin effect. At pharmacological doses used in glucagon-like peptide-1 receptor agonist therapy, this slowing is pronounced and produces nausea, early satiety, and vomiting — the drug is effectively causing gastric retention. These effects are dose-dependent, peak during dose escalation, and typically improve substantially after 4 to 8 weeks as the gastrointestinal tract adapts. Starting at the lowest dose and titrating slowly substantially reduces severity. Glucagon-like peptide-1 receptor agonists do not accelerate intestinal secretion, inhibit pancreatic enzymes, or stimulate gastric acid secretion.

Correct Answer

C — Liraglutide carries a fatty acid chain that allows it to bind albumin in the circulation, protecting it from dipeptidyl peptidase-4 degradation and slowing renal clearance

Rationale

Liraglutide is a human glucagon-like peptide-1 analog modified with a C-16 fatty acid chain. This fatty acid enables non-covalent binding to serum albumin after subcutaneous injection, creating a circulating reservoir that slowly releases active liraglutide. Albumin binding protects the peptide from dipeptidyl peptidase-4 degradation and from renal filtration, extending the half-life to approximately 13 hours and enabling once-daily dosing. This is the same principle as insulin detemir. Microsphere depot technology is used by exenatide once weekly, not liraglutide. Immunoglobulin fragment crystallizable region fusion is the mechanism of dulaglutide. Liraglutide is not protease-resistant across all enzymes — its protection comes from albumin shielding.

Correct Answer

B — Glucagon-like peptide-1 receptors are expressed on thyroid C cells, and sustained receptor activation in rodent studies caused dose-dependent C-cell hyperplasia and tumors, although human relevance remains uncertain

Rationale

Glucagon-like peptide-1 receptors are expressed on thyroid C cells (parafollicular cells that secrete calcitonin). In rodent studies, glucagon-like peptide-1 receptor agonist exposure produced dose-dependent C-cell hyperplasia and, at high doses, C-cell tumors. This signal prompted the contraindication in patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, in whom thyroid C cells may already be susceptible to proliferative stimulation. However, large cardiovascular outcome trials in humans have not confirmed an increased medullary thyroid carcinoma incidence, and human C cells express glucagon-like peptide-1 receptors at lower density than rodent C cells. The contraindication is precautionary, based on rodent data with uncertain human relevance. Glucagon-like peptide-1 receptor agonists do not inhibit calcitonin secretion and do not act on thyroid-stimulating hormone receptors.

Correct Answer

D — The cardiovascular benefit is thought to involve anti-inflammatory and antiatherosclerotic receptor signaling that may require prolonged, sustained receptor engagement; human glucagon-like peptide-1 analogs have longer half-lives and greater receptor occupancy than shorter-acting exendin-4-based agents

Rationale

The mechanism of cardiovascular benefit with glucagon-like peptide-1 receptor agonists is incompletely understood but appears to involve direct anti-inflammatory and antiatherosclerotic effects through receptor signaling in cardiac and vascular tissue, operating partly independently of glucose lowering. The fact that benefit is seen with long-acting human glucagon-like peptide-1 analogs such as liraglutide, semaglutide, and dulaglutide — but not with shorter-acting exendin-4-based agents such as lixisenatide — suggests that sustained, continuous receptor engagement may be required to produce these tissue-level effects. The cardiovascular benefit is not explained by glucose lowering alone, as agents with similar glucose-lowering efficacy differ in their cardiovascular outcomes. Exendin-4-based agents are not renally cleared in a way that produces toxicity, and the dosing frequency explanation is incomplete because exenatide once weekly (comparable receptor engagement duration) also showed cardiovascular neutrality in EXSCEL.

Correct Answer

A — Both liraglutide and semaglutide are human glucagon-like peptide-1 analogs, while lixisenatide is an exendin-4-based agent; cardiovascular benefit has emerged primarily with the human analog subclass

Rationale

Liraglutide and semaglutide are both classified as human glucagon-like peptide-1 analogs — engineered from the native human glucagon-like peptide-1 sequence. Lixisenatide is derived from exendin-4, the Gila monster peptide, sharing only approximately 53 percent homology with human glucagon-like peptide-1. The pattern of cardiovascular outcome trial results — benefit with liraglutide, semaglutide, and dulaglutide (all human analogs); neutrality with lixisenatide and exenatide once weekly (both exendin-4-based) — supports the structural subclass as a relevant distinguishing feature. Liraglutide is a once-daily injection; lixisenatide is also once-daily — so dosing frequency does not explain the difference. Cardiovascular benefit is not explained by weight loss alone or by receptor affinity differences driving cyclic adenosine monophosphate levels.

Correct Answer

C — Liraglutide slows gastric emptying, delaying postprandial glucose absorption and causing glucose levels to be lower than expected during the peak of glimepiride's glucose-independent insulin-stimulating effect

Rationale

When liraglutide is added to a sulfonylurea such as glimepiride, hypoglycemia risk increases through an indirect mechanism: liraglutide slows gastric emptying, delaying the rise in postprandial glucose. Glimepiride continues to close adenosine triphosphate-sensitive potassium channels on beta cells independent of blood glucose, stimulating insulin secretion regardless of whether glucose is rising, normal, or falling. When the postprandial glucose rise is blunted by delayed gastric emptying, glimepiride's ongoing insulin drive lowers glucose further than intended, producing hypoglycemia between meals. This is why guidelines recommend reducing the sulfonylurea dose by 25 to 50 percent when adding a glucagon-like peptide-1 receptor agonist. Liraglutide does not inhibit cytochrome P450 enzymes, does not activate glucagon-like peptide-1 receptors independent of glucose (its own insulin secretory effect is glucose-dependent), and does not displace sulfonylureas from protein binding.

Correct Answer

B — Liraglutide demonstrated a 13 percent reduction in major adverse cardiovascular events in the LEADER trial, while lixisenatide showed cardiovascular neutrality in ELIXA; this outcome trial evidence — not glycemic efficacy — drives the prescribing decision in a patient with established atherosclerotic cardiovascular disease

Rationale

In a patient with established atherosclerotic cardiovascular disease, guidelines recommend selecting an antihyperglycemic agent with proven cardiovascular benefit independent of glycated hemoglobin level. Liraglutide is a human glucagon-like peptide-1 analog with demonstrated major adverse cardiovascular event reduction in LEADER. Lixisenatide is an exendin-4-based agent that showed cardiovascular neutrality in ELIXA — safe but no benefit. The post-myocardial infarction history in this patient makes the difference in cardiovascular outcome trial evidence the deciding factor, not differences in glucose lowering or weight loss. Lixisenatide is not contraindicated after myocardial infarction — ELIXA showed safety, not harm — but it provides no cardiovascular protective effect that liraglutide does.

Correct Answer

D — Sitagliptin

Rationale

Glucagon-like peptide-1 receptor agonists are contraindicated in patients with severe or poorly controlled gastroparesis because they further slow gastric emptying through direct glucagon-like peptide-1 receptor activation in the gastrointestinal tract. In a patient with documented delayed gastric emptying and incompletely controlled gastroparesis symptoms, adding liraglutide, semaglutide, or dulaglutide would predictably worsen gastric retention, nausea, and bloating, and could precipitate severe decompensation. Sitagliptin, a dipeptidyl peptidase-4 inhibitor, raises active incretin levels by inhibiting incretin degradation and enhances glucose-dependent insulin secretion without the direct gastrointestinal motility effects of glucagon-like peptide-1 receptor agonists. It does not slow gastric emptying to a clinically meaningful degree at therapeutic doses, making it the appropriate choice in this patient.

Correct Answer

A — Glucagon-like peptide-1 receptor agonists have been associated with pancreatitis in postmarketing reports; once acute pancreatitis has been attributed to this drug class, restarting the agent risks recurrence and the drug label recommends permanent discontinuation after confirmed pancreatitis

Rationale

Pancreatitis is a recognized adverse effect associated with glucagon-like peptide-1 receptor agonists, reported across the class in postmarketing surveillance. Although large cardiovascular outcome trials have not confirmed a statistically elevated incidence compared with placebo, the drug labels for all agents in this class carry warnings about pancreatitis and explicitly state that the drug should not be restarted after confirmed acute pancreatitis. This recommendation applies regardless of how valuable the drug has been for other indications — in this patient, the cardiovascular benefit of semaglutide, while real, does not override the clinical guideline to discontinue permanently after confirmed pancreatitis attributable to the agent. Semaglutide does not inhibit pancreatic exocrine secretion, is not renally cleared in a way that would cause toxic accumulation after pancreatitis, and does not directly damage acinar cells through a cholecystokinin-ductal mechanism.

Correct Answer

C — Glucagon-like peptide-1 receptors are expressed on thyroid C cells, and sustained activation caused C-cell hyperplasia and tumors in rodent studies; a family history of medullary thyroid carcinoma suggests a possible germline predisposition that could increase susceptibility to C-cell stimulation

Rationale

Glucagon-like peptide-1 receptors are expressed on thyroid C cells, the parafollicular cells that produce calcitonin. In rodent studies, sustained glucagon-like peptide-1 receptor agonist exposure produced dose-dependent C-cell hyperplasia and, at high doses, C-cell tumors. The contraindication for patients with a personal or family history of medullary thyroid carcinoma reflects the concern that individuals with a genetic predisposition — as suggested by a first-degree relative with medullary thyroid carcinoma at a relatively young age — may have C cells that are more susceptible to proliferative stimulation. Familial medullary thyroid carcinoma is often associated with germline mutations in the RET proto-oncogene, as in multiple endocrine neoplasia type 2; however, the drug itself does not directly activate RET — the concern is that already-primed C cells may respond adversely to glucagon-like peptide-1 receptor stimulation. Large human clinical trials have not confirmed an increased medullary thyroid carcinoma incidence, but the contraindication is retained as a precaution because the risk in genetically susceptible individuals cannot be excluded. Glucagon-like peptide-1 receptors are not expressed on thyroid follicular cells, and these drugs do not drive thyroid hormone overproduction.